Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial

Johnny Duerinck; A Vanbinst

Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial

Onderzoeksoutput: Poster

Originele taal-2	English
Status	Published - 2021
Evenement	26th Annual Meeting and Education Day of the Society for Neuro-Oncology - Boston, United States Duur: 18 nov 2021 → 21 nov 2021

Conference

Conference	26th Annual Meeting and Education Day of the Society for Neuro-Oncology
Land	United States
Stad	Boston
Periode	18/11/21 → 21/11/21

Citeer dit

@conference{aa80640d163c4553affa4b2b0aabb983,

title = "Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial",

author = "Johnny Duerinck and A Vanbinst",

year = "2021",

language = "English",

note = "null ; Conference date: 18-11-2021 Through 21-11-2021",

}

Intra-cranial administration of CTLA-4 and PD-1 immune checkpoint-inhibiting monoclonal antibodies in recurrent glioblastoma patients: a multi-cohort adaptive phase I clinical trial. / Duerinck, Johnny ; Vanbinst, A.

2021. Postersessie gepresenteerd op 26th Annual Meeting and Education Day of the Society for Neuro-Oncology
, Boston, United States.

Onderzoeksoutput: Poster